Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.
Epistemonikos ID: b97480c267cf7b4339a53f777115753917eac625
First added on: May 05, 2024